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Abstract This study analyzes the occurrence of epithelial
atypia in 2,833 serially sectioned surgical breast biopsies
(SB) performed for microcalcifications (median number of
blocks per SB:26) and the occurrence of subsequent cancer
after an initial diagnosis of epithelial atypia (median follow-
up 160 months). Epithelial atypia (flat epithelial atypia,
atypical ductal hyperplasia, and lobular neoplasia) were
found in 971 SB, with and without a concomitant cancer in
301 (31%) and 670 (69%) SB, respectively. Thus, isolated
epithelial atypia were found in 670 out of the 2,833 SB
(23%). Concomitant cancers corresponded to ductal carci-
nomas in situ and micro-invasive (77%), invasive ductal
carcinomas not otherwise specified (15%), invasive lobular
carcinomas (4%), and tubular carcinomas (4%). Fifteen out
of the 443 patients with isolated epithelial atypia developed
a subsequent ipsilateral (n=14) and contralateral (n=1)
invasive cancer. The high slide rating might explain the
high percentages of epithelial atypia and concomitant
cancers and the low percentage of subsequent cancer after
a diagnosis of epithelial atypia as a single lesion. Epithelial
atypia could be more a risk marker of concomitant than
subsequent cancer.
Keywords Breast.Epithelialatypia.Lobularneoplasia.
Atypicalductalhyperplasia.Cancer
Introduction
Breast biopsies for infraclinical lesions are more frequent
with mammographic screening programs, but the distribu-
tion of the corresponding histological lesions and their
associations are still imprecise. Difficulties encountered in
following up patients without cancer account for the fact
that the clinical significance of certain non-malignant
lesions and the management of patients are still debated.
Moreover, the problem of surgical biopsy sampling has
never been fully investigated and has added additional
confusion in appreciating the distribution and clinical
significance of such lesions. In 1981, breast epithelial
atypia were hardly mentioned and not clearly defined in the
World Health Organization/International Union Against
Cancer (WHO/UICC) histologic classification of breast
tumors [73]. The histologic classification of noncancerous
lesions has been mainly based on studies analyzing for each
lesion the associated risk of subsequent cancer. These
studies were initiated by the survival studies of Dupont and
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Bordeaux, FrancePage [15, 46] based on lesions discovered by palpation
before the era of mammography. Thereafter, further studies
[6, 9, 17, 24, 31, 51, 62, 67] substantiated these results,
which were ratified in 2003 by the new American Joint
Committee on Cancer (AJCC)/UICC classification of breast
tumors [70]. Schematically, this classification differentiates
benign epithelial lesions (usual ductal hyperplasia and other
lesions) from atypical lesions of ductal or lobular type.
Although this historical classification is challenged by a
new classification [68], it remains the most widely used in
practice. Interestingly, the occurrence of epithelial atypia
was low in Page’s study [46] and has increased with
mammographic screening programs [60, 66] and with the
development of percutaneous large core needle biopsy
(CNB) methods using stereotactic mammography or ultra-
sound guidance. At present, CNB is frequently used for the
initial evaluation of clinically occult breast lesions, thus
generating dilemma for the subsequent management of
certain noncancerous lesions. At our institution, surgical
biopsies (SB) have always been managed in the same way,
and most patients with atypical and malignant lesions have
been followed. The objectives of our work were to analyze
the occurrence of epithelial atypia and their association with
a concomitant cancer in a large series of SB performed for
microcalcifications without a palpable tumor and to assess
the subsequent cancer probability in the group of patients
with an initial diagnosis of epithelial atypia. Finally, we
provide some practical considerations for the management
of patients with epithelial atypia in this era of mammo-
graphic screening and CNB.
Materials and methods
Selection of patients
At Institut Bergonié, from January 1975 to December 2002,
3,166 breast biopsies for diagnostic purposes, 2,833 SB and
333 CNB, were performed for microcalcifications without
any palpable mass in 2,708 patients (mean age 51.8 years,
range 19.7–81 years). Among them, 248 (9%) had several
biopsies in the same or contralateral breast. Since 1998,
microcalcifications have been classified according to the
classifications of the American College of Radiology [2].
SB for diagnostic purposes were defined before 1998 by the
absence of a preoperative diagnosis based on the clinical–
mammographic–cytologic triplet and by the absence of a
positive frozen section and, since 1998, by the presence of
epithelial atypia on CNB. Excluded from this study were
132 cancers and 139 non-atypical benign lesions diagnosed
on CNB as well as 49 re-excisions performed elsewhere
than in our center. Thus, 2,833 SB in 2,375 patients were
available for analysis, among which 13 corresponded to re-
excision after a CNB with epithelial atypia. Since 1989,
needle localization, intraoperative specimen radiography,
and post-excisional biopsy mammography have been
performed in most cases.
Surgical biopsies and tissue sampling: serial macroscopic
sectioning
SB was removed in one fragment and measured more than
3 cm in 94% of the cases (mean size 60 mm, 5–250 mm).
For SB margin assessment, either the surface of the
specimen was inked or the surgeon during the same
operation removed additional tissue in the remaining cavity
after excision of the specimen (surgical margins). After
fixation in Holland Bouin, SB and margin specimens were
serially sectioned in their entirety into numbered slices
every 2 mm [12]. In most cases (89%), careful macroscopic
examination of the specimen failed to reveal any lesion.
Each numbered slice was put in as many numbered separate
cassettes as necessary and paraffin-embedded in sequence.
The median number of blocks per SB was 26 (from 2 to
180) and 8 (from 1 to 44) for surgical margins. Each block
was examined on one hematoxylin–eosin–safran stained
slide.
Classification of lesions and review of slides
Since 1975, all patients have been prospectively included in
our clinical, histologic, and biologic database by senior
pathologists (IM, GMG, IS, JMC). For each SB and each
lesion, we prospectively entered in our pathologic database
morphological descriptive criteria by using 65 pathological
items for noncancerous lesions and 181 for cancers.
Definitions and terminologies given in the literature were
used to report columnar cell lesions (CCL), non-atypical
ductal hyperplasia, atypical ductal hyperplasia, ductal
carcinoma in situ (DCIS), and lobular carcinoma in situ
(LCIS) [1, 4, 7, 10, 17, 19, 21–28, 38, 43–45, 47, 49, 50,
56, 59, 61, 69, 72, 74, 75]. The interest of our database was
to collect morphological descriptive criteria of nearly all the
breast lesions without labeling them. In fact, labels and
definitions of breast lesions have varied throughout the past
30 years, while neither lesions nor their corresponding
descriptive criteria (i.e., size, type, architecture, cellular and
nuclear features, etc...) have changed. The only changes
during this period were the definitions and/or the names
given to these lesions. As we have listed for each lesion all
the corresponding descriptive criteria among the 236
available items, we have been able to reclassify each lesion
according to the “new” criteria recommended by referent
authorities for a new definition, by selecting in our database
the “new” correspondent descriptive criteria corresponding
to this new definition. Consequently, this provided a
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time of our study. For example, low-grade DCIS≤2m m
have been reclassified as atypical ductal hyperplasia/ductal
intraepithelial neoplasia (ADH/DIN) 1B (n=30) according
to the new AJCC/UICC classification of breast tumors [70],
and lesions that we used to term before 1997 [71]a s
clinging carcinoma of the monomorphic type [4] have been
reclassified as flat epithelial atypia (FEA)/DIN 1A or
columnar cell change (CCC) with atypia (n=84) [61].
About half of these 114 cases have been systematically
reviewed by one (IM) or two senior pathologists (IM and
G M Go rI S ) ,a n dt h e r ew a sac o m p l e t ec o n c o r d a n c e
between the second review and the initial descriptive
criteria listed in the database. Similarly, lesions that we
used to name LCIS before 1997 have been renamed lobular
neoplasia (LN) since 1997, corresponding either to atypical
lobular hyperplasia (ALH) or to LCIS. On the contrary, all
the cases with micropapillary lesions were reviewed (n=
155) because there was no item corresponding to precise
descriptive criteria of micropapillations (number, topogra-
phy around the duct, type).
Atypical ductal hyperplasia: definition and sizing
Among the group of ADH/DIN 1B, we individualized two
morphologic types of ADH. Neither had any high-grade
cytological atypia or necrosis.
ADH “mimicking DCIS” (Fig. 1). In this type, architec-
tural atypia were qualitatively insufficient to allow a
diagnosis of DCIS, therefore this “mimicking” DCIS lesion
was classified as ADH whatever its size. Tufts and short
micropapillations formed by cells had a broad base and
were cohesive. There was no polarization of cells, i.e., no
truecribriform spaces.Pseudo-cribriform patterns comprised
irregular or relatively round microlumina with incomplete
polarization of surrounding epithelial cells. Cellular bridges
were wavy without any cellular polarization. Cells corre-
sponded either to columnar cells with uniform ovoid to
elongated nuclei or to cells with a slight increase in the
nuclear/cytoplasmic ratio with more or less distinct cell
borders and round or ovoid nuclei. These cells were
sometimes admixed in the same lesion displaying a
morphological gradient, but there was no regular arrangeent.
Nuclear chromatin was evenly dispersed, homogeneous, or
slightly marginated, and nucleoli were inconspicuous.
Apical snouts, intraluminal secretions, and psammoma-type
calcifications were frequently present.
ADH corresponding to “mini DCIS” (Fig. 2). In this
type, architectural and cytologic atypia corresponded to a
low-grade DCIS but were quantitatively insufficient to
allow a diagnosis of DCIS, therefore this “mini” DCIS
lesion was classified as ADH when ≤2 mm. Tufts and short
micropapillations had a tight base, were present on over all
the periphery of the duct, and were non-cohesive with small
Fig. 1 a–d. ADH “mimicking
DCIS.” a Tufts and short
micropapillations with a broad
base. b Pseudo-cribriform
spaces. c Microlumen with in-
complete polarization of sur-
rounding epithelial cells. d
Cellular bridges without cellular
polarization. Cells are parallel to
the axes (arrows)
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patterns with a polar organization of cells around glandular
spaces and/or variants of cribriform patterns (i.e., trabecular
bars, cartwheel formations, and Roman bridges, Fig. 3)
with polarized cells arranged perpendicular to the axes.
Some solid areas with regular arrangement of cells were
also present. Cells were often small, monomorphous,
sometimes without a columnar change, with a distinct
cytoplasmic membrane and a spaced regular round nucleus
with uniformly dispersed chromatin without prominent
nucleoli. Intraluminal secretions and calcifications (amor-
phous or psammoma-type) were also frequently present
(Fig. 4). When one mini DCIS focus was found in one
partially or completely involved duct/ductular cross-
sections in one terminal ductal lobular unit (TDLU), it
was classified as ADH when it measured ≤2m ma n da s
DCIS when it measured >2 mm. When there were several
foci of “mini” DCIS in close duct/ductular cross-sections
in the same TDLU or in TDLUs located in the same field
at low power magnification (2.5), the lesion was classified
as ADH when its size, i.e., its largest diameter, was
≤2 mm and as DCIS when >2 mm. When there were
several foci of “mini” DCIS in distant duct/ductular cross-
s e c t i o n si nt h es a m eT D L Uo ri nc l o s eT D L U s ,t h es i z eo f
each focus was assessed separately. FEA, rare and
scattered single micropapillations, and cribriform variants
Fig. 2 a–e. ADH corresponding to “mini DCIS.” a A solid mini
DCIS focus measuring less than 2 mm in one TDLU. b Tufts and
short micropapillations over the entire periphery of the duct with small
free papillary tufts in the lumen. c Short micropapillations with a tight
base. d True cribriform spaces. e Microlumen with complete
polarization of surrounding epithelial cells
Fig. 3 a–c. Variants of cribriform patterns. Polarized cells arranged perpendicular to the axes. a Trabecular bars. b Cartwheel formations. c
Roman bridges
4 Virchows Arch (2007) 451:1–10were not taken into consideration for sizing, even if
located in the same TDLU.
FEA were present either as a single lesion or in
association with ADH in the same TDLU and since 1997
have been included in the ADH group. The distinction of
FEA from columnar change without atypia was based on
the criteria given by the WHO for the definition of FEA.
Furthermore, columnar change without atypia was charac-
terized by one or two layers of columnar cells without
nuclear atypia, i.e., no increase in the nuclear/cytoplasmic
ratio, no prominent nucleoli. Nevertheless, some cases of
columnar change with progesterone impregnation, especial-
ly in the second part of the cycle, might display a lobular
distension with a secretory material and large nuclei with
prominent nucleoli. In such cases, myoepithelial cells
displayed the same alterations with clarified cytoplasms,
thus facilitating the diagnosis. The distinction of ADH
mimicking DCIS from usual hyperplasia (UDH) was based
on morphological criteria. Architectural pattern and cyto-
logic criteria of usual ductal hyperplasia were easy to
identify in most cases. UDH corresponded to a proliferation
of epithelial cells in solid or fenestrated areas without any
polarization of surrounding cells. Cells were haphazardly
arranged with overlapping nuclei or were parallel with
characteristic streamings. They were elongated or pseudo
epithelioid, but there was no columnar metaplasia. Cyto-
plasms were more or less abundant with indistinct borders.
Nuclei had irregular size and shape and sometimes
contained a prominent eosinophilic inclusion. In some rare
cases, immunohistochemical staining with cytokeratin 5/6
[41] was used and was negative in ADH mimicking DCIS
and strongly positive in UDH. In some lesions, differential
diagnosis between ADH and low-grade DCIS was all the
more difficult because there were intermediate and intri-
cated morphological aspects in the same TDLU. In practice,
diagnosis of micropapillary lesions was often difficult.
Extensive micropapillary lesions were classified as DCIS
when quantitative and qualitative criteria were simulta-
neously present, i.e., lesion sizing more than 2 mm
corresponding to micropapillations with a tight base over
the entire periphery of the ducts. Additional sections could
be useful for demonstrating more or less qualitative or
quantitative diagnostic criteria. When malignancy remained
equivocal, the case was classified as ADH. When a
concomitant cancer was diagnosed, histologic size was
assessed, and in DCIS, the percentage of blocks with cancer
(“positive blocks”) was specified [13]. Presence and
topography of microcalcifications were also assessed.
Lastly, when FEA and/or “mimicking” DCIS foci were
found on excision margins of a SB with DCIS, a further
surgical resection was not performed.
Follow-up of patients with epithelial atypia as a single
lesion
There were 443 patients with epithelial atypia in one or
several SB, without any previous or synchronous carcinoma
in the same or contralateral breast and treated by biopsy
alone (median follow-up 160months, 7to315). Only 28/443
(6%) were lost to follow-up. Among the 415 other patients,
180 were monitored at our institute and 235 outside by
correspondent specialists working in close relationship with
our institute. All patients received a clinical examination and
mammography once a year. When a new biopsy was
necessary, it was performed at our institute.
Statistical analyses
Comparison of clinical and histologic characteristics was
conducted by using the chi-square test. For women with
epithelial atypia, the probability of developing in situ or
invasive cancer was calculated from the date of the first
biopsy to the earliest event: breast cancer (ipsi- or
contralateral), death, or last contact (last consultation for
the group monitored at our institute and checkpoint date, i.e.,
1 March 2004, for the others). Probabilities were calculated
according to the Kaplan–Meier method (SPSSv11).
Fig. 4 a and b. a Mild cytolog-
ic atypia. b Columnar
cells with uniform ovoid nuclei,
intraluminal calcifications
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Occurrence of epithelial atypia in the 2,833 surgical
biopsies
Epithelial atypia were recorded in 971/2,833 SB (34%).
They were found with and without a concomitant cancer in
301/971 (31%) and 670/971 (69%) of the cases, respec-
tively. Thus, isolated epithelial atypia were found in 23% of
the cases (670 out of the 2,833 SB). Calcifications were
present at histologic examination in 98.6% of SB with
cancer and were located in benign, cancerous, and both
lesions in 10, 39, and 51% of the cases, respectively. In
several cases, cancerous foci without any microcalcifica-
tions were located at points distant from those with
calcifications detected by needle localization.
Types of epithelial atypia
Among the 971 SB with epithelial atypia, there were 101
SB with FEA as a single lesion (11%), 342 (35%) with
ADH, 223 (23%) with LN, and 305 (31%) with ADH and
LN. Thus, ADH was encountered in 647/971 SB (66%).
Types of cancers associated with epithelial atypia
Cancers associated with epithelial atypia corresponded to
DCIS and micro-invasive carcinoma (DCIS-MI) in 233
cases (77%). Among invasive carcinomas (n=68), there
were 13 (9%) lobular and 11 (6%) tubular carcinomas
(Table 1). Cancers were small (≤5 mm in 46% of invasive
carcinomas, fewer than half of the blocks positive in 76%
of DCIS). They were non-high grade in 78 and 67% of
DCIS and invasive carcinoma, respectively. In most cases,
ADH and cancer were situated close to each other. FEA
alone were less frequently associated with a concomitant
cancer than ADH and/or LN (p=5×10
−4).
Cancers without epithelial atypia (malignancy alone)
There were 821 malignant SB without epithelial atypia [590
micro-invasive carcinomas, 206 infiltrating ductal carcino-
mas (IDC), and 25 infiltrating lobular carcinomas (ILC)].
Subsequent cancer in patients with an initial diagnosis
of epithelial atypia as a single lesion
At 5 and 10 years, the probabilities of developing invasive
breast cancer in the group of 443 patients with epithelial
atypia were 2.8% [95%CI=1.4 to 5.5] and 5.5% [95%CI=
3.3 to 9.9], respectively (Fig. 5). Among the 18 subsequent
carcinomas, 15 were invasive (11 IDC and 4 ILC), and 3
corresponded to DCIS. Most subsequent carcinomas were
encountered in the homolateral breast (n=14) and before
10 years (n=16). Seven carcinomas occurred in the group
of patients with an initial diagnosis of LN, in the same (n=
5) or contralateral (n=2) breast. They corresponded to
infiltrating ductal (n=6) or lobular (n=1) carcinomas. The
interval of development was 4, 5, 6 (n=2), 9, and 12 (n=2)
years. Seven carcinomas occurred in the group of patients
with an initial diagnosis of ADH, in the same (n=3) or
contralateral (n=4) breast. They corresponded to DCIS (n=
2) and to infiltrating ductal (n=4) or lobular (n=1)
carcinomas. The interval of development was 1, 2, 3
(n=3), 9, and 12 years. Four carcinomas occurred in the
group of patients with an initial diagnosis of ADH
associated with LN, in the same (n=3) or contralateral
(n=1) breast. They corresponded to DCIS (n=1) and to
infiltrating ductal (n=2) or lobular (n=1) carcinomas. In the
four cases, the interval of development was 4 years. There
was no subsequent carcinoma in the group of patients with
FEA.
Table 1 Types of concomitant cancers (n=301) in the 971 surgical biopsies with epithelial atypia
Epithelial atypia FEA (n=101) ADH (n=342) LN (n=223) ADH+LN (n=305)
No. of cases (%) No. of cases (%) No. of cases (%) No. of cases (%)
Without cancer 84 83 220 64 139 62 227 74
With cancer 17 17 122 36 84 38 78 26
DCIS/DCIS-MI 12 12 103 30 58 26 60 20
IDC/NOS ––16 4.7 17 8 11 3
ILC 1 1 1 0.3 6 3 5 2
TC 4 4 2 1 3 1 2 1
FEA Flat epithelial atypia; ADH atypical ductal hyperplasia; LN lobular neoplasia; DCIS ductal carcinoma in situ; DCIS-MI DCIS with micro-
invasion; IDC infiltrating ductal carcinoma; ILC infiltrating lobular carcinoma; TC tubular carcinoma
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Application of the WHO classification: practical
considerations
For a long time, DCIS was diagnosed even if the character-
istic features were found in only one ductal space [6].
Thereafter, some authors introduced quantitative criteria for
distinguishing between ADH and DCIS [46, 67], while
others [23] rejected them. More recently, Rosen [57–59]
and Schnitt and Vincent-Salomon [61] described CCL
comprising CCC and columnar cell hyperplasia (CCH)
with and without atypia. Nasser [40] challenged this
classification based on columnar shape and limited the
group of lesions to proliferations characterized by a low-
grade atypicality, “atypical columnar cell lesions,” (ACCL)
rather by a columnar cell configuration. In the WHO
classification, ADH includes various not clearly defined
types of lesions (Table 2). On one hand, there are lesions
with arcades, moundings, and micropapillary formations,
but without any true cribriform/complex architectural
patterns [34]. This type of ADH corresponds to the CCH
with atypia of Schnitt and Vincent-Salomon [61] termed
category 3 in Simpson’s study [51], to the definition of
ADH by Koerner [34] and to ADH “mimicking” DCIS in
our study. On the other hand, there are lesions displaying
architectural and cytologic atypia. This type of ADH
corresponds to the complex architectural pattern with
cytologic and architectural atypia of Schnitt and Vincent-
Salomon [61] termed category 5 in Simpson’s study [64], to
the definition of “microfocus of DCIS” by Koerner [34] and
to “mini DCIS” in our study. In Simpson’s study, the ADH/
category 5 contained chromosomal changes and the same
total mean number of changes to that observed in DCIS/
DIN IC, unlike the other CCL. Lastly, because there is still
no consensus for measuring ADH, there is no clear-cut
distinction between ADH and DCIS, and the cut-off at 2 or
3[ 52] mm or at two completely involved spaces [70] seems
arbitrary. While awaiting a definitive molecular classifica-
tion, the simplest attitude could be recommended in routine
Table 2 Terminologies used for intraductal proliferative lesions with low-grade cytologic atypia, so-called atypical columnar cell lesions
Spectrum of
lesions
1, 3–5 Layers No polarization* With polarization
Occasional mounding Mounding, arcades Cribriform spaces
and their variants
No or rare arcades and
micropapillary formations
Cohesive micropapillary
tufts with a broad base
Non-cohesive micropapillary
tufts with a tight base
[70] Flat epithelial atypia/DIN 1A ADH/DIN 1B≤2 mm; or in two spaces DCIS/DIN 1C
[59, 61] Columnar cell hyperplasia with atypia ADH if not extensive DCIS if
extensive
=
Columnar cell change (CCC)
with cytologic atypia
Complex structures with
architectural and cytologic atypia
[34] Columnar cell lesions + ADH Microscopic focus of DCIS DCIS
Institut Bergonié Ex-clinging carcinoma of
monomorphic type
ADH “mimicking” DCIS ADH corresponding to “mini”
DCIS≤2m m
DCIS
[64] CCC with cytologic atypia CCH with architectural
atypia
CCH with architectural atypia DCIS
Or And
CCH with cytologic atypia Cytologic atypia
Regrouping? DIN 1A ADH/DIN 1B ADH/DIN 1C DCIS/DIN 1C
Not measured Measured: ≤3m m > 3m m
*Or incomplete polarization
Fig. 5 Probability of developing subsequent invasive breast cancer in
the group of 415 patients with epithelial atypia (dotted line:
confidence interval 95%)
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grade DCIS foci could be measured and classified as ADH
when equal to or less than 2–3m m[ 52] and as DCIS when
more than 3 mm. Although the mode of measurement in
our study is not under consensus, it is simple and can been
routinely applied.
Occurrence of epithelial atypia and their association
with a concomitant cancer: practical considerations
In our study, the proportion of epithelial atypia is high
(23%), a result difficult to compare to others in the
literature, as the methodologies used by teams are different.
In the Page and Dupont case-control studies [15, 46], ADH
and ALH were found in 2.1 and 1.6% of the cases,
respectively. In mammographic screening programs, epi-
thelial atypia and cancers increase as the number of
biopsies performed for microcalcifications increases, espe-
cially as ACR4/ACR5 lesions are more often excised than
ACR3. However, as underlined by Page [46], “the most
direct relationship of epithelial atypia incidence is to slide
rating.” The number of slides per SB in our study (median
26) was higher than in the other studies on benign breast
lesions: 1–5 in 93% of the cases in the study of Page et al.
[46]( n=283), 3 (range 1–25, n=674) in the study of
Shaaban et al. [62], and a mean of 1.6 slides per cm of
tissue (n=199) in the study of Tavassoli and Norris [67]. In
a recent study conducted in the south west of France in
women aged between 50 and 75 with mammographically
detected non-palpable breast lesions, a similar proportion of
atypical lesions were found when biopsies were serially
sectioned [39]. Furthermore, this high slide rating allowed
the detection of small concomitant cancers in the vicinity of
epithelial atypia in 31% of our cases, with a skew towards
low-grade lesions (high proportions of DCIS and low-grade
invasive carcinomas, especially tubular carcinomas). Our
results strengthen the hypothesis that FEA and ADH are
risk markers of low-grade cancers. This has been confirmed
by the study of Simpson et al. [64] on molecular genetic
profiles of CCL. In some of them, there are both a
morphological and a molecular continuum in the degree
of proliferation and atypia, supporting the hypothesis that
“CCL are a non-obligate, intermediary step in the develop-
ment of some forms of low grade in situ and invasive
carcinoma.” The association of epithelial atypia with a
concomitant cancer in nearly one third of the cases in our
study parallels previous findings concerning the frequency
of cancers found in SB performed for atypia in CNB. Thus,
approximately 30% [20, 29] and 15 to 21% [5, 8, 14, 18,
35, 45, 53, 63, 76] of excisions after CNB with ADH and
LN, respectively, were proven to have cancer. Consequent-
ly, excision is recommended [45] for all patients in whom
ADH is identified on CNB and may be justified in patients
with FEA, as they are included in the spectrum of ACCL.
Excision remains a controversial issue in patients with LN.
Some authors have advocated it [3, 18, 33, 63], while
others have rebutted it [55], especially when LN is an
incidental non-extensive finding [48]w i t hn or a d i o l o g i c –
pathologic discordance [18] and without any synchronous
mass lesion [37]. SB corresponding to re-excision should
be processed in its entirety by serial macroscopic
sectioning [32, 65]. When pathologic examination is
exclusively focused on mammographic calcifications, the
risk is to underestimate the DCIS size/extension because
cancerous foci without any calcification (10% in our study
vs 6% in Owing’study) [42] may be located at points distant
from those with benign breast tissue containing calcifications.
Subsequent cancer after an initial diagnostic of epithelial
atypia as a single lesion: practical considerations
In the literature, 4 to 22% (average interval 8.3 years
follow-up) [6, 42, 67] and 15 to 20% [16, 30, 56]o f
patients developed invasive carcinomas after a diagnosis of
ADH and LN, respectively. The risk of developing cancer
increases with extended follow-up, but many cancers after a
diagnosis of LN have a good prognosis and a low mortality
[36]. These results are difficult to compare to ours because
the methodologies are different. The low probabilities of
subsequent invasive cancer in our study could be due to the
high slide rating, allowing the detection of small concom-
itant cancer that might have been missed with a low slide
rating and inadequate patient management [11, 54].
In conclusion, when epithelial atypia are present, they
are associated in nearly one third of the cases with a
concomitant close cancer and are found as isolated lesions
in nearly 23% of SB performed for microcalcifications. In
practice, ADH should be more clearly defined with simple
guidelines for measuring lesions. When malignancy
remains equivocal and/or when sizing is difficult, it is
better to classify the lesion as ADH. Epithelial atypia could
be more a “risk factor” of a concomitant geographically
small close cancer than a risk marker for a subsequent
cancer, as they form part of a spectrum of lesions [64].
References
1. Allred DC, Mohsin SK, Fuqua SA (2001) Histological and
biological evolution of human premalignant breast disease.
Endocr Relat Cancer 8:47–61
2. American College of Radiology (1993–2003) Breast imaging
reporting and data system (BI-RADS). American College of
Radiology, Restion, VA
3. Arpino G, Allred DC, Mohsin SK, Weiss HL, Conrow D, Elledge
RM (2004) Lobular neoplasia on core-needle biopsy—clinical
significance. Cancer 101:242–250
8 Virchows Arch (2007) 451:1–104. Azzopardi JG (1979) Problems in breast pathology. Saunders,
Philadelphia
5. Berg WA, Mrose HE, Ioffe OB (2001) Atypical lobular
hyperplasia or lobular carcinoma in situ at core-needle breast
biopsy. Radiology 218:503–509
6. Bodian CA, Perzin KH, Lattes R, Hoffmann P, Abernathy TG
(1993) Prognostic significance of benign proliferative breast
disease. Cancer 71:3896–3907
7. Brogi E, Oyama T, Koerner FC (2001) Atypical cystic lobules in
patients with lobular neoplasia. Int J Surg Pathol 9:201–206
8. Burak WE Jr, Owens KE, Tighe MB, Kemp L, Dinges SA,
Hitchcock CL et al (2000) Vacuum-assisted stereotactic breast
biopsy: histologic underestimation of malignant lesions. Arch
Surg 135:700–703
9. Carter CL, Corle DK, Micozzi MS, Schatzkin A, Taylor PR (1988)
A prospective study of the development of breast cancer in 16,692
women with benign breast disease. Am J Epidemiol 128:467–477
10. The Consensus Conference Committee (1997) Consensus confer-
ence on the classification of ductal carcinoma in situ. Cancer
80:1798–1802
11. Crisi GM, Mandavilli S, Cronin E, Ricci A Jr (2003) Invasive
mammary carcinoma after immediate and short-term follow-up for
lobular neoplasia on core biopsy. Am J Surg Pathol 27:325–333
12. de Mascarel I, Trojani M, Bonichon F, Coindre JM (1993)
Histological examination of 2859 breast biopsies. Analysis of
adequate sampling. Pathol Annu 28(1):1–13
13. de Mascarel I, Bonichon F, MacGrogan G, de Lara CT, Avril A,
Picot V, Durand M, Mauriac L, Trojani M, Coindre JM (2000)
Application of the van Nuys prognostic index in a retrospective
series of 367 ductal carcinomas in situ of the breast examined by
serial macroscopic sectioning: practical considerations. Breast
Cancer Res Treat 61:151–159
14. Ditkoff BA, Smith SJ, Brenin D (2001) The management of
lobular neoplasia identified at percutaneous core breast biopsy.
Breast Cancer Res Treat 69:306 (Abstract)
15. Dupont WD, Page DL (1985) Risk factors for breast cancer in
women with proliferative breast disease. N Engl J Med 312:146–
151
16. Dupont WD, Page D (1987) Breast cancer risk associated with
proliferative disease, age at first birth, and a family history of
breast cancer. Am J Epidemiol 125:769–779
17. Dupont WD, Parl FF, Hartmann WH, Brinton LA, Winfield AC,
Worrell JA, Schuyler PA, Plummer WD (1993) Breast cancer risk
associated with proliferative breast disease and atypical hyperpla-
sia. Cancer 71:1258–1265
18. Elsheikh TM, Silverman JF (2005) Is follow-up surgical excision
indicated when breast core needle biopsies show atypical lobular
hyperplasia or lobular carcinoma in situ: a correlative study of 33
patients with review of the literature. Am J Surg Pathol 29
(4):534–543
19. Elston CW, Ellis IO (1998) The breast. In: Symmers W St C (ed)
Systemic pathology, 3rd edn. Churchill Livingstone
20. Ely KA, Carter BA, Jensen RA, Simpson JF, Page DL (2001) Core
biopsy of the breast with atypical ductal hyperplasia: a probabilistic
approach to reporting. Am J Surg Pathol 25:1017–1021
21. Report of pathologists of the working group “Breast Cancer
Screening” of the European Union (1996) European recommen-
dations for quality assurance in the setting of mammographic
screening for breast cancer. Ann Pathol 16:315–333
22. Eusebi V, Feudale E, Foschini MP, Micheli A, Conti A, Riva C,
Di Palma S, Rilke F (1994) Long-term follow-up of in situ
carcinoma of the breast. Semin Diagn Pathol 11:223–235
23. Fisher ER, Costantino J, Fisher B, Palekar AS, Redmond C,
Mamounas E (1995) Pathologic findings from the National Surgical
Adjuvant Breast Project (NSABP) Protocol B-17. Intraductal
carcinoma (ductal carcinoma in situ). The National Surgical
Adjuvant Breast and Bowel Project Collaborating Investigators.
Cancer 75:1310–1319
24. Fitzgibbons PL, Henson DE, Hutter RV (1998) Benign breast
changes and the risk for subsequent breast cancer: an update of the
1985 consensus statement. Cancer Committee of the College of
American Pathologists. Arch Pathol Lab Med 122:1053–1055
25. Foote Jr FW, Stewart FW (1945) Comparative studies of
cancerous versus non cancerous breasts. Basic morphologic
characteristics. Ann Surg 121:6–23
26. Fraser JL, Raza S, Chorny K, Connolly JL, Schnitt SJ (1998)
Columnar alteration with prominent apical snouts and secretions:
a spectrum of changes frequently present in breast biopsies
performed for microcalcifications. Am J Surg Pathol 22:1521–
1527
27. Fraser H, Raza S, Chomy K, Connoly JL, Schnitt SJ (2000)
Immunophenotype of columnar alteration with prominent apical
snouts and secretions (CAPSS). Lab Invest 80:21A
28. Goldstein NS, O’Malley BA (1997) Cancerization of small ectatic
ducts of the breast by ductal carcinoma in situ cells with apocrine
snouts: a lesion associated with tubular carcinoma. Am J Clin
Pathol 107:561–566
29. Gupta A, Diaz LK, Wiley EL (2004) Atypical duct hyperplasia
and lobular neoplasia diagnosed by core needle biopsy: incidence
of up staging to DCIS and invasive carcinoma. Mod Path 17:33A
(USCAP Abstract 123)
30. Haagensen CD, Lane N, Lattes R, Bodian C (1978) Lobular
neoplasia (so-called lobular carcinoma in situ) of the breast.
Cancer 42:737–769
31. Hutter RVP (1985) Goodby to “fibrocystic disease”. N Engl J
Med 312:179
32. International Consensus Conference (2002) Image-detected breast
cancer: state of the art diagnosis and treatment. Breast J 8:70–76
33. Jacobs TW, Conolly JL, Schnitt SJ (2002) Non malignant lesions
in breast core needle biopsies: to excise or not to excise? Am J
Surg Pathol 26:1095–1110
34. Koerner FC (2004) Epithelial proliferations of ductal type. Semin
Diagn Pathol 21:10–17
35. Liberman L, Sama M, Susnik B, Rosen PP, La Trenta LR, Morris
EA, Abramson AF, Derschaw DD (1999) Lobular carcinoma in
situ at percutaneous breast biopsy: surgical biopsy findings. AJR
Am J Roentgenol 173:291–299
36. McLaren BK, Schuyler PA, Sanders M, Jensen RA, Simpson JF,
Dupont WD, Page DL (2005) Tumor type and Nottingham grade
of invasive carcinoma following atypical lobular hyperplasia on
initial breast biopsy. Mod Path 18:42A, (USCAP Abstract 182)
37. Middleton LP, Grant S, Stephens T, Stelling CB, Sneige N, Sahin
AA (2003) Lobular carcinoma in situ diagnosed by core needle
biopsy: when should it be excised? Mod Path 16:120–129
38. Moinfar F, Man YG, Bratthauer GL, Ratschek M, Tavassoli FA
(2000) Genetic abnormalities in mammary ductal intraepithelial
neoplasia-flat type (“clinging ductal carcinoma in situ”): a
simulator of normal mammary epithelium. Cancer 88:2072–2081
39. Monnereau A, MacGrogan G, Rabreau M, Dilhuydy MH,
Demeaux JL, Ochoa A, le Groupe Anatomo Pathologistes
Aquitains (GAPA), Buestel ML (2006) Evaluation de l’activité
sénologique des anatomo-cyto-pathologistes aquitains avant dépo-
stage organisé: étude prospective sur trois mois. Rev Epidémiol
Santé Publique 54(4)
40. Nasser SM (2004) Columnar cell lesions: current classification
and controversies. Semin Diagn Pathol 21:18–24
41. Otterbach F, Bankfalvi A, Bergner S, Decker T, Krech R, Boecker
W (2000) Cytokeratin 5/6 immunohistochemistry assists the
differential diagnosis of atypical proliferations of the breast.
Histopathology 37:232–240
42. Owings DV, Hann L, Schnitt SJ (1990) How thoroughly should
needle localization breast biopsies be sampled for microscopic
Virchows Arch (2007) 451:1–10 9examination? A prospective mammographic/pathologic correla-
tive study. Am J Surg Pathol 14:578–583
43. Oyama T, Maluf H, Koerner F (1999) Atypical cystic lobules: an
early stage in the formation of low-grade ductal carcinoma in situ.
Virchows Arch 435:413–421
44. Oyama T, Iijima K, Takei H, Horiguchi J, Iino Y, Nakajima T,
Koerner F (2000) Atypical cystic lobule of the breast: an early stage
of low-grade ductal carcinoma in-situ. Breast Cancer 7:326–331
45. Pacelli A, Rhodes DJ, Amrami KK (2001) Outcome of atypical
lobular hyperplasia and lobular carcinoma in situ diagnosed by
core needle biopsy: clinical and surgical follow-up of 30 cases.
Am J Clin Pathol 116:591, (Meeting abstract)
46. Page DL, Dupont WD, Rogers LW, Rados MS (1985) Atypical
hyperplastic lesions of the female breast. A long-term follow-up
study. Cancer 55:2698–2708
47. Page DL, Anderson TJ (1987) Diagnostic histopathology of the
breast. Churchill Livingstone
48. Page DL, Kidd TE, Dupont WD, Simpson JF, Rogers LW (1991)
Lobular neoplasia of the breast: higher risk for subsequent
invasive cancer predicted by more extensive disease. Hum Pathol
22:1232–1239
49. Page DL, Rogers LW (1992) Combined histologic and cytologic
criteria for the diagnosis of mammary atypical ductal hyperplasia.
Hum Pathol 23:1095–1097
50. Page DL, Jensen RA (1996) Hypersecretory hyperplasia with
atypia in breast biopsies. What is the proper level of clinical
concern? Pathol Case Rev 1:36–40
51. Palli D, Rosselli DT, Simoncini R, Bianchi S (1991) Benign breast
disease and breast cancer: a case-control study in a cohort in Italy.
Int J Cancer 47:703–706
52. Pathology Reporting of Breast Disease (2005) A joint document
incorporating the 3rd edn. of the NHSBSP’s guidelines for
pathology reporting in breast cancer screening and the 2nd edn.
of The Royal College of Pathologists. Minimum Datas for Breast
Cancer Histopathology, NHSBSP Publication 58
53. Philpotts LE, Shahen NA, Jains KS et al (2000) Uncommon high-
risk lesions of the breast diagnosed at stereotactic core needle
biopsy: clinical importance. Radiology 216:813–817
54. Renshaw AA, Cartagena N, Derhagopian RP, Gould EW (2002)
Lobular neoplasia in breast core needle biopsy specimens is not
associated with an increased risk of ductal carcinoma in situ or
invasive carcinoma. Am J Clin Pathol 117:797–799
55. Renshaw AA (2004) Minimal (< or =0.1 cm) invasive carcinoma
in breast core needle biopsies. Incidence, sampling, associated
findings, and follow-up. Arch Pathol Lab Med 128:996–999
56. Rosen PP, Kosloff C, Lieberman PH, Adair F, Braun DW Jr (1978)
Lobular carcinoma in situ of the breast. Detailed analysis of 99 patients
with average follow-up of 24 years. Am J Surg Pathol 2:225–251
57. Rosen PP (1999) Breast pathology: diagnosis by needle core
biopsy. Lippincott, Williams & Wilkins, Philadelphia, PA
58. Rosen PP (1999) Columnar cell hyperplasia is associated with
lobular carcinoma in situ and tubular carcinoma. Am J Surg
Pathol 23:1561
59. Rosen PP (2001) Rosen’s breast pathology. Lippincott, Williams
& Wilkins, Philadelphia, PA
60. Rubin E, Visscher DW, Alexander RW, Urist MM, Maddox WA
(1998) Proliferative disease and atypia in biopsies performed for
nonpalpable lesions detected mammographically. Cancer 61:
2077–2082
61. Schnitt SJ, Vincent-Salomon A (2003) Columnar cell lesions of
the breast. Adv Anat Pathol 10:113–124
62. Shaaban AM, Sloane JP, West CR, Moore FR, Jarvis C, Williams
EM, Foster CS (2002) Histopathologic types of benign breast
lesions and the risk of breast cancer: case-control study. Am J
Surg Pathol 26:421–430
63. Shin J, Rosen PP (2002) Excisional biopsy should be performed if
lobular carcinoma in situ is seen on needle core biopsy. Arch
Pathol Lab Med 126(6):697–701
64. Simpson PT, Gale T, Reis-Filho JS, Jones C, Parry S, Sloane JP,
Hanby A, Pinder SE, Lee AHS, Humphreys S, Ellis IO, Lakhani
SR (2005) Columnar cell lesions of the breast: the missing link in
breast cancer progression? A morphological and molecular
analysis. Am J Surg Pathol 29:734–746
65. Standard, Options et Recommandations (2001) Cancers du sein
non métastatiques, vol 3. FNCLCC, p 29
66. Stomper PC, Cholewinski SP, Penetrante RB, Harlos JP, Tsangaris
TN (1993) Atypical hyperplasia: frequency and mammographic
and pathologic relationships in excisional biopsies guided with
mammography and clinical examination. Radiology 189:667–671
67. TavassoliFA,Norris HJ(1990)Acomparisonof theresults oflong-
term follow-up for atypic intraductal hyperplasia and intraductal
hyperplasia of the breast. Cancer 65:518–529
68. Tavassoli FA (1998) Ductal carcinoma in situ: introduction of the
concept of ductal intraepithelial neoplasia. Mod Path 11:140–154
69. Tavassoli FA (1999) Pathology of the breast, 2nd edn. Appleton
and Lange
70. Tavassoli FA, Devilee P (2003) Pathology and genetics. In:
Tumours of the breast and female genital organs. Word Health
Organization classification of tumours, pp 60–76
71. Trojani M (1988) Atlas en couleur d’histopathologie mammaire.
Maloine, Paris
72. Tsuchiya S (1998) Atypical ductal hyperplasia, atypical lobular
hyperplasia and interpretation of a new borderline lesion. Jpn J
Cancer Clin 44:548–555
73. Types histologiques des tumeurs du sein (1981) In: Classification
Histologique Internationale des Tumeurs. Organisation Mondiale
de la Santé, Genève
74. Weidner N (1995) Malignant breast lesions that may mimic
benign tumors. Semin Diagn Pathol 12:2–13
75. Wellings SR, Jensen HM, Marcum RG (1975). An atlas of
subgross pathology of the human breast with special reference to
possible precancerous lesions. J Natl Cancer Inst 55:231–273
76. Zhang RR, O’Hea BJ, Brebbia JR et al (2001) Atypical lobular
hyperplasia or lobular carcinoma in situ on large core needle
biopsy of the breast: is surgical excision necessary? Am J Clin
Pathol 116:610 (Meeting abstract)
10 Virchows Arch (2007) 451:1–10